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Abstract
Extracellular matrix (ECM) degradation is a critical process in tumor cell invasion and requires matrix degrading
protrusions called invadopodia. The Na+/H+ exchanger (NHE1) has recently been shown to be fundamental in the
regulation of invadopodia actin cytoskeleton dynamics and activity. However, the structural link between the
invadopodia cytoskeleton and NHE1 is still unknown. A candidate could be ezrin, a linker between the NHE1 and the
actin cytoskeleton known to play a pivotal role in invasion and metastasis. However, the mechanistic basis for its role
remains unknown. Here, we demonstrate that ezrin phosphorylated at T567 is highly overexpressed in the
membrane of human breast tumors and positively associated with invasive growth and HER2 overexpression.
Further, in the metastatic cell line, MDA-MB-231, p-ezrin was almost exclusively expressed in invadopodia lipid rafts
where it co-localized in a functional complex with NHE1, EGFR, ß1-integrin and phosphorylated-NHERF1.
Manipulation by mutation of ezrins T567 phosphorylation state and/or PIP2 binding capacity or of NHE1s binding to
ezrin or PIP2 demonstrated that p-ezrin expression and binding to PIP2 are required for invadopodia-mediated ECM
degradation and invasion and identified NHE1 as the membrane protein that p-ezrin regulates to induce invadopodia
formation and activity.
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Introduction
The dissemination of metastasis is the leading cause of
cancer fatality, underlying the need for new therapeutic
approaches specifically focusing on tumor cell spreading to
distant sites [1]. Despite considerable progress in our
understanding of cancer biology, leading to discovery of novel
biological treatments, limitations in our understanding of
invasion/metastasis has limited development of anti-metastatic
therapies [2]. The invasive process requires changes in tumor
cell adhesion properties, cell motility and proteolytic remodeling
of the extracellular matrix (ECM). It is now well established that
aggressive tumor cells have a specific structure dedicated to
promoting their increased invasive ability: the Beta1 (ß1)-
integrin activated, protease and actin rich plasma membrane
structures called invadopodia, that play a central role in driving
cancer cell dissemination in the body through the directed
proteolysis of the ECM [3-7]. Indeed, the amount of matrix
degradation associated with invadopodia activity has been
shown to directly correlate with invasive potential making it
crucial to understand their dynamics in order to design efficient
treatments against metastasis.
However, the complex molecular mechanisms governing the
formation and function of invadopodia are still not well
understood making the elucidation of the basic mechanisms of
invadopodia-driven tumor invasion a major challenge in tumor
biology. While there have been many studies looking at the
proteins that regulate cytoskeletal organization such as Arp
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2/3, WASP, cortactin and the small G-protein Cdc-42 [8 for
review], there has yet been no study concerning how the
cytoskeletal actin core of the invadopodia interacts with and is
bound to the membrane of the invadopodia. In this respect, we
still know fairly little concerning the interplay of biochemistry
and cell structure that underlies their development and function
[3,5,6].
In this respect, recent advances have revealed that the Na
+/H+ exchanger type 1 (NHE1) is localized at invadopodia and
its activity has a double function in driving both ß1 integrin-
stimulated invadopodia formation and their proteolytic activity
through (i) the acidification of the extracellular peri-invadopodia
nanospace which is necessary for ECM proteolysis [9] and (ii)
the alkalinization of the invadopodia cytosol which causes the
release of cofilin from cortactin to stimulate the dynamic
process of invadopodia protrusion [10]. Interestingly, both EGF
[9,10] and tumor hypoxia [11] enhance cancer cell
invasiveness through invadopodia formation by promoting
NHE1 activity.
The structural mechanisms by which NHE1 and the actin
cytoskeleton in invadopodia are functionally interconnected has
remained undefined. In the above papers, it was hypothesized
that members of the ERM (ezrin, radixin, moesin) family of
adapter proteins could be the probable physical linkers of the
NHE1 to the invadopodia actin cytoskeleton since one of the
members, ezrin, has been shown to bind to both NHE1 and F-
actin and to participate in their reciprocal regulation [12-14].
Ezrin contains an N-terminal domain that recruits a variety of
membrane receptors/transporters and a C-terminal domain
termed the COOH-terminal ERM-associated domain (C-
ERMAD) that binds to the actin cytoskeleton, characteristics
which create functional complexes that regulate many
processes [15,16], including cell proliferation, survival and
apoptosis [17], migration [17,18], spatiotemporal control of
various signaling molecules including cAMP [19] and the
formation of microvilli [20-22].
In line with these functions, recent studies have identified a
central role for ezrin in multiple malignancies. It has been
reported to be overexpressed in diverse cancers where it
correlates with aggressive stage and poor prognosis [23-40]. A
recent paper reported that ezrin overexpressing rectal tumors
had a shorter time to local recurrences [41] (Jörgren et al.,
2012). In line with these patient data, experimental
manipulation of ezrin expression with siRNA or overexpression
decreases or increases, respectively, motility and/or invasion in
a variety of cell lines [42-52].
Interestingly, a shift from apical membrane to cytoplasmic
expression of ezrin has been associated with dedifferentiation,
invasiveness, and poor prognosis in colorectal [53], head &
neck [54] and breast cancer [55,56]. This suggests that
abnormal cellular localization of ezrin may lead to the
deregulation of several functions in tumor cells that lead to
metastasis, including the acquisition of an invasive phenotype
and further suggests that a probable post-translational
modification of ezrin is taking place as cancer progresses. In
this respect, it is well known that ezrin is activated by
conformational changes triggered by a sequential binding of
ezrin N-terminal FERM (band 4.1, ERM) domain to
phosphatidylinositol 4,5-biphosphate (PIP2) followed by
phosphorylation of a conserved threonine residue (T567) in its
C-terminal domain [57,58]. The phosphorylation step stabilizes
ezrin binding to the actin cytoskeleton and restricts its binding
to specialized membrane domains [15] where the active ezrin
assembles and integrates signaling molecules to exert diverse
downstream effects [58]. Importantly, while some of the
functional studies observed that it was the phosphorylated form
of ezrin to drive metastasis [42-45,47,48,51], the underlying
mechanism is still unknown.
Altogether, these studies demonstrate that not only the
expression level of ezrin but also its phosphorylation status and
subcellular localization should be considered to better
understand its role in tumor progression. However, in breast
cancer information on the relationships between ezrin, p-ezrin
and clinical-pathological tumor characteristics are lacking.
Furthermore, while the above studies suggest that ezrin plays a
role in breast cancer progression, neither its specific
mechanism(s) of action in driving cancer nor the signal
transduction systems involved in its contribution to the
metastatic spreading of breast tumors have so far been
described. The aim of this study was to provide a bridge
between in vivo and in vitro studies to better understand the
role and dynamics of p-ezrin in metastasis.
Here, we observe that p(T567) ezrin is overexpressed in the
membrane in aggressive human breast tumors and in the
invadopodia in invasive breast cancer cells where it forms
protein-protein signaling complexes with NHE1, ß1-integrin,
EGFR and phosphorylated NHERF1. Further, p-ezrin
enhances NHE1 activity at invadopodia, invadopodial-
dependent ECM proteolysis and cell invasion, thus inducing an
invasive phenotype in breast cancer cells in vitro by
coordinating an ECM proteolytic/invasion signal module. We
hypothesize that binding to the ECM through the ß1-integrin
receptor locally induces ezrin phosphorylation at T567 which
promotes the NHE1 signal complex activating it and leading to
(i) an altered cytoskeletal organization and the development of
the invadopodia [9,10] and (ii) an increased NHE1-dependent
H+-efflux with its consequent matrix proteolysis [9]. The present
study adds ezrin in its T567 phosphorylated state as an
important player in the understanding the molecular
mechanisms behind the cancer invasive process. We believe
that p-ezrin could serve as a marker potentially applicable to
the detection and identification of pre-symptomatic cancers
and, secondly, could be exploited as a therapeutic target in
those cancers.
Results
Phospho(pT567)-ezrin expression is associated with
more aggressive metastatic progression, poor
prognosis and HER-2 expression
To investigate the role of ezrin and p(T567)-ezrin in breast
cancer invasion, we assessed their expression and distribution
in human breast cancer tissues. We first asked whether total
and phospho-ezrin are overexpressed in human breast tumors
and how their relative localization may change with
progression. Relative total and phospho-ezrin protein
invadopodia Ezrin T567 Phosphorylation
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expression was measured with Immunohistochemistry (IHC).
Figure 1A shows typical IHC staining for ezrin and p-ezrin in
tissues derived from a normal breast or from tumors of different
grades. As recently reported [59], in the normal lobule total
ezrin is highly localized in and limited to the apical membrane
while in the lower grade tumors total ezrin is heavily localized in
the cytosol and shifts to a more plasma membrane localization
as the the tumor advances. New to this study, p-ezrin was
always localized to the plasma membrane. A case study of 75
consecutive subjects (Figure 1B), verified that total ezrin
increased its plasma membrane localization as the tumors
progressed and, importantly, that the relative amount of p-ezrin
strongly increased as the tumor grade increased (Figure 1C)
while that of total ezrin did not change (data not shown).
We then correlated p-ezrin protein expression measured as
above in primary breast tumors with respect to patient clinico-
pathological disease characteristics such as age, tumor size,
proliferation index (Ki67), presence of regional nodal
metastases (Lymph Node), and Progesterone receptor status,
tumor cytohistological de-differentiation (Grade), HER2
receptor status and Nottingham Prognostic Index (NPI) (Table
1). Overall p-ezrin protein expression significantly increased
with increasing age, tumor cytohistological de-differentiation
(Grade), proliferation (Ki-67) and with a poorer prognosis as
indicated by an increasing Nottingham Prognostic Index (NPI)
[60]. Correlation analysis further revealed that tumor p-ezrin
protein expression levels were positively correlated with
increasing levels of the proto-oncogene receptor HER2/ErbB2
[61,62]. This association with HER2 was also observed in an
immunofluorescence analysis of a histological section from a
patient in which an architecturally disorganized, tumor lobule
strongly co-expressed HER2 (green) and p-ezrin (red) at the
membrane (Figure 1D).
Phospho (T567)-ezrin is enriched in invadopodia and
co-localizes with cortactin, NHE1 and ß1-integrin
While these clinical data indicate that plasma membrane p-
ezrin expression is related overall to a more aggressive
phenotype of breast cancer, the mechanism(s) involved in its
role as a metastasis promoter are unknown. We were
particularly intrigued by the strong correlation with HER2,
suggesting that p-ezrin expression could be related to invasive
properties, which plays a critical role in driving metastatic
progression [63]. Therefore, we next went on to determine its
expression, interaction with other proteins in invadopodia, the
invasive organ of metastatic cells, and its role in invasion.
As a starting point of the study of the p-ezrin regulation of
focal invadopodial-dependent ECM degradation, we measured
the association of total and p-ezrin expression with focal
proteolytic ECM degradation and with the expression of the
actin nucleation factor and invadopodia marker, cortactin. We
first utilized the classic technique in which cells are plated on
top of a chemically cross-linked layer of 2% porcine gelatin
labeled with rhodamine and focal digestion is observed as the
removal of background red substrate fluorescence. As shown
in Figure 2A, cells of the highly invasive human breast cancer
line, MDA-MB-231, incubated on this gelatin overnight,
removed focal zones of gelatin observed as non-fluorescent
areas both under the cell body and at the cell periphery.
Confocal immunofluorescence analysis of the expression of the
invadopodial marker, cortactin (blue) and endogenous p-ezrin
(green) showed that these two proteins were associated with
areas of focal digestion and, further, were often colocalized
(see white arrowheads for examples) in various focal digestive
zones.
To obtain a quantitative comparison of the distribution of
various proteins in invadopodia, cells plated as above on 2%
cross-linked gelatin were fractionated for cytosol, cell
membrane and invadopodia fractions as previously described
[9] assayed by Western Blotting for total ezrin, p-ezrin and p-
ERM (Figure 2B, upper panel) and for NHE1, CFTR, cortactin,
Figure 1.  Analysis of ezrin and p-(T567) ezrin expression
and localization in human normal and breast cancer.  (A)
representative immunolocalization (IHC) of total ezrin and p-
ezrin in a normal breast and in breast tumor sections of
increasing Grade from left to right panels, bar equals 10µm.
The increased ezrin and p-ezrin expression in the large
disorganized, breast tumor lobules (t) displays diffuse
distribution in the cells of the lobule while normal, organized
breast lobules (n) have a strictly apical distribution. (B)
Histogram showing that total ezrin in tumor samples increases
its relative membrane localization as Grade increases. (C)
Histogram showing that relative p-ezrin expression in tumor
samples increases as Grade increases. (D)
Immunofluorescence was directly performed for HER2 (green)
and p-ezrin (red) in a breast tumor section. The merge and the
magnification of the area in the white square shows that there
was a high amount of co-localization of the two proteins in the
membrane. bar = 10µm.
doi: 10.1371/journal.pone.0075113.g001
invadopodia Ezrin T567 Phosphorylation
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Protein Kinase A (PKA) and the receptors EGFR, ß1-integrin
and CD44 (Figure 2C). These Western Blot measurements in
the three fractions showed that p-ezrin, p-ERM and cortactin
were all very over-expressed in the invadopodial fraction
compared to the membrane fraction. An analysis of p-ezrin and
p-ERM expression standardized to total ezrin expression
(Figure 2B, lower panel) showed that in invadopodia almost all
of the ezrin present was phosphorylated at T567 while a very
small fraction of ezrin was phosphorylated in the membranes of
the rest of the cell. As gelatin principally activates ß1 integrin,
we stimulated the cells with the ß1 integrin activating antibody,
P4G11, to determine if the phosphorylation of ezrin at T567
was a direct consequence or not of the activation of this
receptor. As can be seen in Figure S1A, the specific activation
of the ß1 integrin results in a rapid increase in p-ezrin that was
maximal at 24 hours. Interestingly, Figure 2C shows that, of the
three receptors assayed, ß1 integrin and EGFR were
Table 1. Association of pEzrin expression with clinico-
pathological parameters.
 pEzrin - pEzrin+ Tot=75  
 n % n % tot P value
Age       
30-59 24 70 10 30 34 0.034
60-90 19 46 22 54 41  
Grade       
I 20 83 3 17 24 0.0056
II 14 50 14 50 28  
III 9 39 14 61 23  
Lymph node       
Negative 33 62 20 38 53 NS
Positive 10 45.5 12 54.5 22  
Dimension       
Negative 22 58 16 42 38 NS
Positive 21 57 16 43 37  
PgR       
Negative 8 44.5 10 55.5 18 NS
Positive 34 61 22 39 56  
HER2       
Negative 40 63.5 23 36.5 63 0.013
Positive 3 25 9 75 12  
Ki-67       
Negative 34 65 18 35 52 0.012
Positive 7 33 14 67 21  
NPI       
GPG (<2.5) 25 67 12 33 37 0.048
MPG (2.5-3.5) 13 59 9 41 22  
PPG (>4.5) 5 31 11 69 16  
Phospho(T567)-ezrin (p-ezrin) expression was measured in IHC; n = 75 breast
carcinomas (median age 60). Significance between median p-ezrin expression
values for Grade and NPI were evaluated by the Kruskal-Wallis non-parametric
ANOVA test while the Mann-Whitney non-parametric test was applied to age, size,
Ki-67, node status and receptor status. NPI: Nottingham Prognostic Index. GPG:
Good Prognostic Group; MPG: Medium Prognostic Group; PPG: Poor Prognostic
Group.
doi: 10.1371/journal.pone.0075113.t001
expressed in both the membrane and invadopodia fractions
while CD44 was found to be expressed almost exclusively in
the membrane fraction. This primarily membrane distribution of
CD44 was verified in confocal analyses of cells plated on
Matrigel containing DQ-BSA (Figure S2).
To better visualize invadopodia entrapped in the ECM, we
removed the cell body of cells incubated for 6 hr on this 2%
cross-linked porcine gelatin as previously described [9] and
then directly performed confocal immunofluorescence for actin
and p-ezrin expression in the invadopodia that remained inside
the gelatin (Figure 2D). In confocal immunofluorescence inside
the gelatin layer, p-ezrin and actin were observed to co-localize
in various groups of invadopodia and Z-analysis showed that
the invadopodia were approximately a micron in width and
ranged from 3 to 5µm in length consistent with the size and
form of invadopodia reported in studies utilizing combined
confocal and electron microscopy [64]. Statistical analysis of
their co-localization by the calculation of the Li’s Intensity
Correlation Quotient (ICQ) of the variance in the distribution of
the two proteins, demonstrated that actin and p-ezrin
localization at invadopodia were highly co-dependent
(ICQ=0.427 ± 0.035, n = 3, p<0.001).
Since the localization of invadopodial activity by the removal
of entrapped fluorescence in the ECM does not permit a direct
analysis of the proteins associated with proteolytic activity, we
next used a modified protocol that we developed based on the
degradation-dependent release of fluorescence of a quenched
fluorophore (DQGreen-BSA) that has been dissolved in a
thicker, non cross-linked matrix layer comprised either of a
single ECM component such as collagen I or of the natural,
complex mixture found in Matrigel [9]. In this protocol, digestion
is observed as the appearance of unquenched fluorescence in
a dark background rather than as the removal of high
background fluorescence. Importantly, this protocol also gives
a more sensitive measure of the initiation and/or low levels of
digestion and, further, permits the quantification of local
proteolytic activity, the high-resolution mapping of individual
focal cleavage sites and a more exact confocal co-localization
between focal digestion and proteins of interest. Preliminary
three color fluorescence confocal microscopy experiments in
cells cultured on DQGreen-BSA Matrigel for 6 hrs
demonstrated that, indeed, actin was co-localized with cortactin
in the areas of observed focal proteolysis of ECM bound
DQGreen-BSA in a highly significant manner in Matrigel (data
not shown). These properties of the actin/cortactin punctate
digestive structures are clearly consistent with that of
invadopodia reported previously [3-5] and ‘invadopodial’
structures formed in Matrigel by the same cell line [9].
Identical experiments demonstrated that p-ezrin was co-
localized with cortactin in the areas of observed focal
proteolysis of ECM bound DQGreen-BSA in a highly significant
manner in Matrigel (Figure 3A). Therefore, we next examined
the association of p-ezrin and NHE1 (Figure 3B) expression
with ECM focal digestion in three color fluorescence confocal
microscopy in cells cultured on DQGreen-BSA-Matrigel for 6
hours and observed that NHE1 highly co-localized with both p-
ezrin and focal ECM proteolysis both along the edge of the cell
as well as at the tip of leading edge pseudopodia. The size of
invadopodia Ezrin T567 Phosphorylation
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these p-ezrin/cortactin and p-ezrin/NHE1 expressing
proteolytic, invadopodial structures were very similar to those
observed above in Figure 2 and Z sectioning revealed that
these structures protruded vertically from the ventral
membrane into the Matrigel substrate at sites of focal ECM
degradation with a size of the proteolytic structures
(invadopodia) very similar to those observed above on
crossed-linked gelatin: approximately 1 µm in diameter and 3-5
µm in length. RGB analysis of the Z-sections showed that the
indeed actin colocalization occurred in areas of focal digestion.
Furthermore, Intensity Correlation Analysis (ICA, panels under
images) and the Li’s Intensity Correlation Quotient (ICQ) of the
Z-sections revealed a high co-dependence between the
distribution of p-ezrin and cortactin or NHE1 (ICQ = 0.381 ±
0.015, n = 3, p < 0.001 and 0.403 ± 0.21, n = 3, p < 0.001 for
the p-ezrin/cortactin and p-ezrin/NHE1, respectively).
p-ezrin binds NHE1 and ß1 integrin/EGFR in a ternary
complex in tumor cells
The fractionational and confocal co-localization suggested
the possibility that p-ezrin could be directly involved in the
regulation of NHE1 activity in the tumor cells. Ezrin and p-ezrin
scaffolding function is mediated by its binding to other proteins
via its N-terminal domain (N-ERMAND) and NHE1 is a known
partner of ezrin [12-14]. To analyze this possible physical/
biochemical association between p-ezrin and NHE1 and
Figure 2.  p-(T567) ezrin is preferentially expressed in invadopodia.  Invadopodia protein expression on 2% cross-linked gelatin
layers. (A) Confocal immunofluorescence micrograph of MDA-MB-231 cells cultured on cross-linked rhodamine (TRITC)-conjugated
gelatin. Matrix degradation is visualized as loss of red fluorescence background and cells were stained with anti-cortactin antibody
(blue) and anti-p-ezrin antibody (green). There was widespread, focalized zones of degradation and cortactin and p-ezrin were both
localized and often co-localized in digested areas as indicated by white arrow in both representative axial (XY) and sagittal (XZ)
sections. Representitive IF of 3 independent experiments. Scale bars = 10 µm. (B & C) To better visualize invadopodia entrapped in
the ECM, the cell bodies of cells incubated for 6 hr on a layer of 2% cross-linked gelatin were removed and separated into cytosol
and plasma membrane while entrapped invadopodia were extracted from the gelatin as described in Methods. Proteins of the three
fractions were assayed in Western Blot analysis. The upper panel of (B) shows the expression of p-ezrin with a specific antibody
and with an antibody for all the forms of phosphorylated ERM proteins and an antibody for total, non-phosphorylated ezrin, while the
lower panel displays a histogram of the relative expression of p-ezrin or p-ERM to total ezrin in the three fractions, n= 12. p<0.001
with respect to expression in the invadopodia. (C) expression of a series of proteins to determine their relative expression in the
fractions. (D) Using the above scraping protocol on coverslips, immunofluorescence was directly performed for p-ezrin (green) and
actin (red) in the invadopodia that remained in the cross-linked gelatin. Representitive IF of 4 independent experiments. Axial (XY)
and sagittal (XZ) sections show a high co-localization of p-ezrin and actin in invadopodia. Scale bars = 2 µm.
doi: 10.1371/journal.pone.0075113.g002
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identify other members of this protein-protein complex, we
conducted co-immunoprecipitation (co-IP) experiments and
immunoblot analysis for each of the putative complexed
proteins with anti-ezrin, anti-p-ezrin and anti-NHE1 in the
membrane (m) and invadopodia (i) fractions isolated as above
from cells plated on 2% gelatin (Figure 4A). We utilized aliquots
from each fraction to measure the input expression of the three
proteins in each fraction and the self-identification of each
protein in the immunocomplex to verify the success of the
immunoprecipitation. While the ‘input’ NHE1 was more
expressed in the membrane (M) fraction, the antibody against
p-ezrin precipitated NHE1 much more strongly in the
invadopodia fraction (I) that in the membrane fraction (M) and
the antibody against total ezrin only weakly precipitated NHE1
in either fraction. The antibodies against all three proteins
much more strongly precipated p-ezrin in the invadopodia
fraction, reflecting its proportional expression levels.
Reciprocially, the amount of p-ezrin bound to the NHE1- and
total ezrin- immunocomplexes was much stronger in the
invadopodia fraction than in the membrance fraction. These
data demonstrate that p-ezrin directly binds to NHE1 in the
invadopodia and support the confocal IF experiments showing
their co-localization in the invadopodia (Figure 3B).
The organization of discrete, functional macromolecular
signaling complexes is now known to constitute a critical level
of biological activity and their construction is orchestrated by
scaffolding proteins containing modular interaction domains
that facilitate the association of multiple target proteins. The
multifunctional scaffolding protein NHERF1 has been
demonstrated to be a major component of signaling complexes
Figure 3.  p-ezrin is expressed and co-localized with NHE1 in invadopodia of cells on Matrigel.  To better visualize
invadopodial focal digestion and protein localization in Matrigel, we developed an in situ zymography technique using the quenched
fluorescent substrate, DQ-Green-BSA, such that a quantifiable fluorescence is released only upon digestion of the matrix. Cells
seeded on Matrigel were allowed to digest the fluorigenic substrate and after fixation cells were assayed in immunofluorescence.
The images show (A) cortactin and p-ezrin and (B) NHE1 and p-ezrin immunolocalization at BSA proteolytic spots (green) in axial
planes taken at the bottom of the cells (XY). For each of the two fields, XZ zoomed sections of the above representative regions of
interest (red box) are shown at the side. As can be seen in green, low levels of basal, diffuse digestion were observed under and
around the cells together with more restricted areas of high levels of focal digestion. Representative IFs of 5 independent
experiments. Scale bar = 10 µm. Right panels: XZ plane and relative magnification of indicated area show the high co-localization of
cortactin and NHE1 with p-ezrin and proteolysis in RGB analysis. Lower panels: ICA analysis plots using the JACoP image analysis
plugin in ImageJ of cortactin/p-ezrin and NHE1/p-ezrin shows their highly significant co-localization. Average ICQ values for all the
experiments are presented in the text.
doi: 10.1371/journal.pone.0075113.g003
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and binds to ezrin to regulate membrane dynamics through its
c-terminal ERM binding domain [20-22]. Both the non-
phosphorylated (approximately 50 kDa) and phosphorylated
(approximately 55 kDa) NHERF1 bands were expressed in
both the invadopodia and membrane fractions. As shown by
the immunocomplexes for each of the three proteins (Figure 4;
IP: NHE1; IP: p-ezrin; IP: total ezrin), while the total ezrin
immunocomplex precipitated both the 50kDa and 55kDa
(phosphorylated) forms of NHERF1, both the p-ezrin- and
NHE1- immunocomplexes precipitated only the 55kDa
NHERF1 band. These data suggest that it is only
phosphorylated NHERF1 that actively participates in the
formation of a p-ezrin-NHE1-NHERF1 protein-protein complex
and in its regulation of invadopodia function. Ezrin also has an
important role as an “A Kinase Anchoring Protein“ (AKAP) in
which it binds to the regulatory subunit of Protein Kinase A
(PKA) to finely regulate its localization and target proteins.
Interestingly, all three immunocomplexes much more strongly
precipitated the PKA regulatory II subunit in the invadopodia
fraction, reflecting its proportional expression levels.
In order to determine the possible inclusion of the ß1-integrin
and EGF receptors in a signaling complex with p-ezrin, we also
performed Western Blotting of these proteins in
immunocomplexes from the plasma membrane (m) and
invadopodia (i) cell fractions of cells that had been plated on
2% gelatin. As seen in Figure 4B, both ß1-integrin and EGF
receptors precipitated with the p-ezrin immunocomplex
preferentially in the invadopodia fraction, demonstrating a
probable direct active involvement of these receptors with the
p-ezrin protein-signalling complex. In order to determine the
possible direct binding of the ß1-integrin receptor with p-ezrin,
we performed two types of experiments. Firstly, we examined
the association of p-ezrin and ß1-integrin (Figure S3A)
expression with ECM focal digestion in three color fluorescence
confocal microscopy in cells cultured on DQGreen-BSA-
Matrigel for 6 hours and observed that ß1 integrin highly co-
localized with both p-ezrin and focal ECM proteolysis.
Secondly, to further analyze the potential direct association
between p-ezrin and ß1 integrin at proteolytically active
invadopodia, we used an in situ Proximity Ligation Assay (in
situ PLA), which can detect endogenous protein-protein
interactions that occur within 40 nm [65] combined with the
Matrigel degradation assay (Figure S3B). Indeed, as shown by
the red fluorescent staining (upper left panel), p-ezrin
associates with ß1 integrin in a large subset of foci of degraded
matrix. Interestingly, there are a couple of ‘digestive’ podosome
(doughnut shaped structures, white arrows) where proteolysis
occurred mostly within the circle. These results demonstrate
that some sub-populations of p-ezrin and ß1 integrin closely
interact in functionally active invadopodia where they probably
both interact with NHE1.
Altogether, these data suggest that stimulation of cancer
cells to develop invadopodia by plating on ECM, occurs
through the formation of a protein-protein complex formed by
NHE1, p-ezrin, ß1-integrin, PKA and p-NHERF1.
Figure 4.  p-ezrin binds NHE1, p-NHERF1, PKA and ß1 integrin/EGFR in a ternary complex in tumor cells.  (A) MDA-MB-231
cells were seeded for 24 hr on 2% gelatin and cytosol, cell body membrane and invadopodia fractions were separated as above.
Each cell membrane or invadopodia fraction was then immunoprecipitated with anti-NHE1, anti-p-ezrin or anti-ezrin and the
precipitated immunocomplex was probed for the expression of NHE1, p-ezrin, NHERF1 and RIIß subunit of PKA by Western Blot.
(B) the fractions were immunoprecipitated with anti-p-ezrin and the precipitated immunocomplex was probed for the expression of
ß1 integrin and EGF receptors by Western Blot. Protein input for each protein was measured by Western Blot of the total input with
the same antibodies. Representitive blots of 4 independent experiments.
doi: 10.1371/journal.pone.0075113.g004
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NHE1 and p-ezrin are preferentially associated with
lipid rafts in the invadopodia fraction
Caveolin-1 containing lipid rafts are dynamic plasma
membrane platforms that promote specific protein clustering
and the formation of functional signalling complexes [66]. Lipid
rafts are highly present in invadopodia membranes and are
proposed to be required for both invadopodia formation and
function [67-70]. Therefore, we further fractionated the
membrane and invadopodia isolated fractions into raft (pellet)
and nonraft (supernatant, supernat) fractions. As can be seen
in Figure 5A, total ezrin and p-ezrin expression were
associated with different lipid fractions in invadopodia
suggesting that in invadopodia ezrin shifts its localization to
lipid rafts when it becomes phosphorylated as has been
described in other cell types [50]. Importantly, NHE1 and p-
ezrin were preferentially localized in the lipid raft fraction,
suggesting that this co-localization of the activated p-ezrin with
NHE1 could be involved with their above observed functional
interaction. The co-localization of NHE1 and p-ezrin with
flotillin-1 clearly shows that these proteins are associated with
lipid rafts suggesting that the raft organization is important for
the complex formation and invadopodia function. Furthermore,
the possible active involvement of the ß1-integrin and EGF
receptors in the signaling complex was further supported by
their localization in the invadopodial raft fraction (Figure 5A).
To functionally test if the presence of lipid rafts is critical, the
cells were subjected to a mild cholesterol depletion with 1 mM
methyl-β-cyclodextrin (MßCD) for 1 hr at 37 °C to disrupt lipid
rafts and the proteolytic capacity of their invadopodia were
measured as above. As can be seen in Figure 5B and C,
MßCD treatment reduced proteolytic activity by more than 80%
while maintaining the general cell shape and total surface
expression of the NHE1 (Figure 5D) demonstrating that a
change in transporter distribution but not number probably
accounts for the inhibition of ECM proteolytic activity. Taken
together, these results suggest that cholesterol depletion has
an effect on p-ezrin/NHE1 function and are consistent with
previous work demonstrating the importance of lipid rafts in the
regulation of NHE1 [71-74]. We propose these interactions
occur in caveolin-1-containing lipid rafts in the invadopodial
Figure 5.  NHE1 and p-ezrin are localized in the same lipid raft fraction in the invadopodia but not in the membrane
compartments and lipid raft cholesterol is necessary for invadopodia function.  (A) Raft (pellet) and nonraft (supernatant,
Supernat) fractions were separated from the above membrane and invadopodia fractions by incubating the fractions (100 µg
protein) at 4°C with lysis buffer containing 1% of Lubrol. Insoluble material was collected into pellets (centrifugation at 100,000 X g
for 1 hour), and equal amounts of the resuspended pellet (P) and the supernatant (SN) were analyzed by Western Blotting for
NHE1, p-ezrin, total ezrin, EGFR and ß1-integrin. Quality of separation was determined by immunoblotting for flotillin-1, a marker for
lipid rafts. Representative blots are shown (n = 3). To determine the effect of cholesterol depletion on invadopodia function, MDA-
MB-231 cells were incubated for 30 minutes at 37°C in the presence (MβCD-treated) or absence (untreated) of 0.5% MβCD as
described in Methods and invadopodia-dependent ECM digestion was analyzed in confocal microscopy for a series of individual
cells as described in Methods; (B) typical images of digestion for 6 hrs and overnight in cells treated or not. (C) histogram of a series
of experiments performed as in (B). Mean ± S.E.M., n=3, ***p<0.001 for focal proteolysis compared to the control cells. (D) NHE1
immunofluorescence of vehicle or MβCD treated cells demonstrating a change in transporter distribution but not total expression.
bar = 10 µm.
doi: 10.1371/journal.pone.0075113.g005
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compartment and are responsible for an increased ECM
degradative activity.
Relevance of ezrin T567 phosphorylation and its
binding to PIP2 and/or NHE1 in regulating invadopodia
proteolytic activity, NHE1 activity and invasion
We first approached the question of the role of increased
endogenous p-ezrin expression in invadopodia by
overexpressing constructs of (i) ezrin mutated in the T567
domain to either no longer be able to be phosphorylated
(T567A) or to mimic phosphorylation (T567D) together with an
ezrin construct that cannot bind to phosphatidylinositol 4,5-
bisphosphate (PIP2-). The mean total invadopodia proteolytic
activity of each cell was then assessed by the release of
quenched Bodipy fluorescence in Matrigel assays as described
in the Methods section (Figure 6A).
The analysis of Matrigel proteolysis revealed that
transfection of the MDA-MB-231 cells with the phosphorylation
dead T567A ezrin mutant (pd) resulted in an approximately
60% reduction of focal ECM proteolysis while transfection of
the phosphorylation mimic T567D mutant (pmim) doubled their
total proteolytic capacity. Similar results were obtained when
the cells were incubated with 1µM of NSC668394 (NSC, 3rd
set of lanes of Figure 6A), a compound that inhibits ezrin
phosphorylation at T567 [75]. The activation of ezrin can also
occur subsequent to its binding to phosphatidylinositol 4,5-
bisphosphate (PIP2), a lipid that is selectively concentrated at
the apical surface of polarized epithelia [57,58] and which is
also expressed in invadopodia [76]. As can also be seen in
Figure 6A, transfection of cells with the ezrin construct in which
its binding to PIP2 is abolished (PIP2-) significantly reduced the
total ECM proteolytic capacity to levels similar to the phospho-
dead (pd) mutant. Moreover, to assess if both ezrin
phosphorylation and its interaction with PIP2 are necessary for
invadopodial activity and if they interact, we transfected the
cells with double mutants for phosphorylation and PIP2
binding. Importantly, the double negative mutant construct
(PIP2-/pd) did not further reduce ECM proteolytic invadopodial
activity, whereas transfection with the double mutant construct
containing the negative PIP2 binding mutation together with the
phosphorylation mimic mutation (PIP2- & pmim) annulled the
effect of the two mutations, suggesting that the binding of ezrin
with the membrane component PIP2 is also a prerequisite for it
regulation of invadopodial activity as previously observed in
other cellular systems [57,58] and that they are acting through
the same signal cascade. To determine if this phosphorylation
of ezrin is part of the ß1 integrin invadopodia signaling network
and is necessary for the ß1 integrin stimulation of invadopodia-
driven proteolysis, we stimulated cells plated on DQ-labeled
Matrigel with 5 mg/ml of an activating antibody against ß1
integrin (P4G11) in the absence or presence of the p-ezrin
inhibitor, NSC668394. As can be seen in Figure S1B, in control
conditions treatments with the activating antibody stimulated
focal proteolysis by approximately 2.4-fold and this stimulation
was almost completely abrogated in the presence of the
inhibitor.
On the basis of these data on ECM proteolysis together with
reports in various tumor cell lines that p(T567)-ezrin (p-ezrin)
Figure 6.  Ezrin phosphorylation and binding to PIP2 and
NHE1 binding to both ezrin and PIP2 are necessary for
invadopodia proteolytic activity.  (A) To examine the role of
ezrin T567 phosphorylation and/or binding to PIP2 in
invadopodial-dependent focal digestion of the ECM, MDA-
MB-231 cells were (A) transfected with empty cDNA (Control)
or plasmids contain ezrin cDNA mutated in the T567 site to be
either phosphodead (pd) or phosphomimic (pmim) or mutated
in the ezrin PIP2 binding site such that it no longer can bind
PIP2 (PIP2-) or treated with 1µM of the inhibitor of ezrin T567
phosphorylation, NSC668394 (NSC). (B) To examine the role
of NHE1 binding to either ezrin or PIP2 in invadopodia
proteolysis, MDA-MB-231 cells were transfected with an NHE1
mutant lacking the ability to bind to ezrin (KR/A 556-564-NHE1-
HA) or to bind to PIP2 (KR/A 513-520-NHE1-HA).
Two days after transfection, cells were plated on Matrigel with
DQ-Green BSA and, 24 hr later, ECM digestion was analyzed
in confocal microscopy for a series of individual cells as
described in Methods. Mean ± S.E.M., n=4, ***p<0.001 for
focal proteolysis compared to the control cells.
doi: 10.1371/journal.pone.0075113.g006
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drives invasion (see Introduction), we next tested the effect of
these mutants on invasion using a 3D invasion assay where
the cells must cross a thick layer of Matrigel (Figure 7). Indeed,
invasive capacity followed quite closely the pattern of the effect
of the ezrin mutants on focal ECM proteolysis, in line with
studies suggesting that invadopodia function and p-ezrin are
fundamental for cancer cell invasive capacity.
Relevance of NHE1 binding to ezrin and PIP2 in
regulating invadopodia proteolytic activity
If ezrin regulates invasive activity through its modulation of
NHE1 activity then we can hypothesize that we will find a
similar regulatory pattern of invadopodia ECM proteolysis as
we observed above with the ezrin mutants with NHE1 mutants
that cannot bind either ezrin (KRA 556-564) or (KRA 513-520)
PIP2 (Figure 6B). Indeed, while over-expression of the wild-
type (WT) NHE1 construct increased focal digestion by
approximately 45%, cells transfected with either the ezrin
binding-defective mutant of NHE1 (KRA 556-564) or the PIP2
binding-defective mutant of NHE1 (KRA 513-520) had a greatly
reduced amount of focal matrigel digestion compared to cells
transfected with the empty vector. While this inhibition is lower
than that reported in cells transfected with the ion transport-
defective mutant (E266I) of NHE1 [9], it does compare closely
with the amount of inhibition observed above with the ezrin
mutants.
Altogether these results suggest that both the
phosphorylation of ezrin and its interaction with PIP2 are
indispensable in controlling invadopodial NHE1 activity and the
consequent focal proteolytic capacity, as well as in establishing
a compartmentalized functional “signalsome” that allows this
activation of invadopodial proteolytic activity. Interestingly, the
activity of NHE1 can also be directly regulated by its binding to
PIP2 suggesting that the PIP2-dependent regulation of its
activity could occur through a dynamic interaction of the two
pathways and introduces an additional layer of regulation of
invadopodia activity between the cytoskeleton and the
membrane.
Discussion
While a potential role for ezrin in breast tumor progression
has recently been demonstrated in immunohistochemical
studies that observed an elevated expression and altered
localization in breast tumors compared to adjacent normal
breast tissue (see Introduction), to date there has not been an
evaluation of the clinical-pathological parameters associated
with the overexpression of its activated, T567 phosphorylated
form (p-ezrin). Here we observe, in a series of breast tumors
(Figure 1A-C; Table 1), that while total ezrin changes its
localization with progression, p-ezrin remains membrane bound
and increases it expression such that it is highly overexpressed
in tumors. Further, this overexpression is associated with
increasingly aggressive clinical characteristics, with poor
prognosis and with increasing HER2 expression, a marker of
breast cancer invasion and metastatic progression [61,62].
Altogether, these in vivo data predict that p-ezrin would make a
novel tumor prognostic marker. This evident and significant
increase in p-ezrin expression at the membrane of the more
aggressive tumors together with the high co-localization with
the oncogene HER2, suggested that p-ezrin expression and
function could be related to aggressive behavior. While in vitro
studies have demonstrated that p-ezrin increases invasion and
metastasis, the precise mechanism(s) involved in its role as an
invasion promoter are unknown. We were particularly intrigued
by the strong correlation with HER2, suggesting that p-ezrin
expression could be related to invasion, which plays a critical
role in driving metastatic progression. Therefore, we next went
on to determine its expression, interaction with other proteins
and role in invasion and in invadopodia, the invasive organ of
metastatic cells.
Activation of ß1 integrin through integrin-mediated cell
substrate adhesion at point contacts constitutes the primary
spatial cue leading to the recruitment of ECM-degrading
enzymes and formation of a polarized plasma membrane
extraflection domain (invadopodia) which penetrates the
underlying ECM to produce its focal proteolysis and permit the
invasion of the tumor cell [3-7]. Here we present data to
demonstrate that binding to the ECM through the ß1-integrin
Figure 7.  Ezrin phosphorylation and binding to PIP2 are
necessary for invasion.  To examine the role of ezrin T567
phosphorylation and/or binding to PIP2 in invasive capacity,
MDA-MB-231 cells were transfected with empty cDNA
(Control) or plasmids containing ezrin cDNA mutated in the
T567 site to be either phosphodead (pd) or phosphomimic
(pmim) or mutated in the ezrin PIP2 binding site such that it no
longer can bind PIP2 (PIP2-). Two days after transfection, a
quantitative measure of the degree of in vitro invasion of MDA-
MB-231 cells was measured as the ability to traverse a 8 µm
polycarbonate membrane coated with 5 µg matrigel (Chemicon
Int., Livermore, CA) as previously described (Cardone et al.,
2005). The fluorescent samples were read in a fluorescence
plate reader at 480/520 nm (Cary Eclipse Fluorescence
Spectrophotometer, Varian). Mean ± S.E., n=5, ***p<0.001 and
n.s. is not significant.
doi: 10.1371/journal.pone.0075113.g007
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receptor promotes the local phosphorylation of ezrin at T567
which facilitates the formation of a lipid raft localized signalling
complex that promotes NHE1-dependent invadopodia
formation and proteolytic activity [7,9,10]. Indeed, the specific
activation of the ß1 integrin with an activating antibody (P4G11)
rapidly phosphorylated ezrin (Figure S1A) and stimulated
invadopodia-dependent focal proteolysis that was abrogated by
NSC668394, a pharmacological inhibitor of ezrin
phosphorylation at T567 (Figure S1B).
As a scaffolding protein, p-ezrin generates spatiotemporal
asymmetry at the cell cortex to organize transmembrane
proteins with the actin cytoskeleton in-order-to integrate both
structure and signaling at the apical junctional complex of
polarized epithelial cells which underlies cell polarization and
asymmetric cell division [15-18]. In invasive cancer cells, one
could predict that the activated form of ezrin, phosphorylated
on T567, would increase its relative expression in the organelle
dedicated to invasion. Indeed, in Western Blot analysis of
isolated fractions we observed that while total ezrin expression
was lower in the invadopodia than in the other cell
compartments, it was expressed almost entirely in the T567
phosphorylated form while in the rest of the cell the relative
level of phosphorylated ezrin was quite low. This preferential
invadopodial localization of p-ezrin was confirmed with confocal
microscopy on both gelatin and Matrigel and co-localized with
NHE1 and ß1-integrin in the invadopodia. These direct
interactions were confirmed in co-IP experiments in the isolated
fractions where p-ezrin immunocomplexes contained both
NHE1 and the ß1-integrin receptor preferentially in the
invadopodia.
Caveolin-1 containing lipid rafts, also known as caveolae, are
cholesterol- and sphingolipid-enriched dynamic platforms at the
plasma membrane which promote specific protein clustering
that promotes the formation of functional signaling complexes
[66]. These lipid rafts are highly present in the membranes of
invadopodia and are proposed to be required for both
invadopodia formation and ECM degradative activity [67-70].
Furthermore, in some cancer cells NHE1 has been shown to
be localised in caveolin-containing lipid rafts which contributes
to regulating its activity and, presumably, its interaction with
other proteins [71-74]. Lipid raft fractionation confirmed that in
the invadopodia p-ezrin shifts to lipid rafts where it found with
the NHE1 together with EGFR and ß1-integrin, suggesting that
raft organization is important for the signaling complex
formation and invadopodia function. Indeed, cholesterol
depletion almost completely blocked invadopodia proteolysis,
in line with previous reports [67,69]. We propose that lipid rafts
in the invadopodial compartment constitute the platform where
these interactions occur and are responsible for a regulated
ECM proteolytic activity.
Lastly, we used a set of ezrin and NHE1 mutants to dissect
the role and possible mechanism of p-ezrin and PIP2 in
regulating invadopodia proteolytic action. We found that,
indeed, removal of the possibility to phosphorylate ezrin at
T567 (T567A, pd) greatly reduced invadopodial proteolytic
activity while, conversely, a mutant where the threonine at
position 567 is replaced by a negatively charged aspartate,
which mimics a permanent phosphorylation (T567D, pmim)
resulted in a greatly increased proteolytic capacity of the
invadopodia. Importantly, incubation with a pharmacological
inhibitor of ezrin phosphorylation at T567 (NSC668394) also
reduced invadopodia activity, suggesting that the observed
reduction in invasion and metastases in mice treated with NSC
[75] is due to a reduced invadopodia activity. The activation of
ezrin can also occur through its binding to PIP2, a lipid that is
selectively concentrated at the apical surface of polarized
epithelia [57,58] and which is also expressed in invadopodia
[76]. Indeed, transfection of cells with the ezrin construct in
which its binding to PIP2 is abolished (PIP2-) significantly
reduced the total ECM proteolytic capacity and invasion to
levels similar to the phospho-dead (pd) mutant. Moreover, in
cells transfected with double mutants for phosphorylation and
PIP2 binding, the double negative mutant construct (PIP2-/pd)
did not further reduce ECM proteolytic invadopodial activity,
whereas co-transfection of the PIP2 negative ezrin mutant
construct together with the phosphorylation mimic (PIP2- &
pmim) construct annulled the effect of the two mutations on
both invadopodia proteolytic activity and invasion. It is well
known that ezrin is activated by a sequential binding to PIP2
followed by T567 phosphorylation [57,58] and our data show
that the binding of ezrin with membrane PIP2 is also a
prerequisite for its regulation of invadopodial activity.
The hypothesis that invadopodia p-ezrin overexpression
influences their activity in breast cancer cells, at least in part,
through the regulation of the NHE1 is further supported by the
similar regulatory pattern of invadopodia ECM proteolysis with
NHE1 mutants that cannot bind either ezrin or PIP2 (Figure 6B)
as was observed above with the ezrin mutants. Indeed, while
over-expression of the wild-type (WT) NHE1 construct
increased focal digestion by approximately 45%, cells
transfected with either the ezrin binding-defective mutant (KRA
556-564) or the PIP2 binding-defective mutant (KRA 513-520)
of NHE1 had a greatly reduced amount of focal Matrigel
digestion compared to cells transfected with the empty vector.
While this inhibition is lower than that reported in cells
transfected with the ion transport-defective mutant (E266I) of
NHE1 [9], it does compare closely with the amount of inhibition
observed above with the ezrin mutants.
Interestingly, the activity of NHE1 can also be directly
regulated by its binding to PIP2 suggesting that a versatile p-
ezrin-PIP2-NHE1 complex exists where regulation of NHE1
activity could occur through a dynamic interaction of the two
pathways and introduces an additional layer of regulation of
invadopodia activity between the cytoskeleton and the
membrane. Indeed, the localization of the signaling complex in
invadopodia lipid rafts could possibly increase the local PIP2
concentration creating not only a protein-protein signalsome
complex but a dynamic protein-lipid-protein signalsome
complex connected to the actin cytoskeleton that is able to
modulate rapidly and precisely the cellular response to
changing conditions. NHE1 is targeted by hypoxia [77] and
hypoxia was found to stimulate invadopodial localized NHE1
[11] and, therefore, in this way NHE1 constitutes an important
point of integration between the interaction of the tumor cell
with the ECM through integrin receptors and the metabolic
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tumor microenvironment and could also be important for the
design of novel anti-metastasis therapies.
The mechanism by which p-ezrin stimulates the invadopodial
NHE1 is poorly known at present. Signaling modules are
orchestrated by scaffolding proteins and a growing body of
evidence now indicates that one such scaffolding protein,
NHERF1, through its direct binding to ezrin plays an important
role in modulating its function. The active, open form of ezrin
(p-ezrin) colocalizes with NHERF1 at or near the plasma
membrane of polarized cells where they reciprocally stabilize
each other and function together in organizing macromolecular
complexes [15,16]. Our identification here of p-ezrin as a
crucial molecule in breast cancer dissemination suggests that
the roles of NHERF1 [78] and NHE1 [78,79] in directing
metastasis may well be governed by p-ezrin. Indeed, we find
here that it is a phosphorylated form of NHERF1 that binds to
the ß1-integrin/p-ezrin/NHE1 complex that forms in the lipid
rafts of the invadopodia to finely regulate the development and
function of the invadopodia, by selecting and eventually
integrating the various signals arriving at the cell. Intriguingly, a
similar polarized distribution and interaction of p-ezrin and p-
NHERF1 have been shown to be fundamental components of
the development of microvilli in a number of epithelial cell types
[20-22]. The present data suggest that microvillar growth and
development may have profound similarities to the tumor
invasive structure and that the trans-differentiation represented
by invadopodia in aggressive cells may represent the
subversion of the normal microvillar machinery by the invasive
tumor cell.
We hypothesize that the protein reorganization in the
invadopodia occurs, in part, through binding of phosphorylated
NHERF1 with still unidentified sub-membrane proteins. It has
been reported that phosphatidyl inositol-4-phosphate 5-kinase
(PIP5K), which regulates PIP2 formation [76], interacts with
NHERF1 [80] and that active RhoA-GTP affects ezrin activation
by the involvement of its effectors Rho Kinase (ROCK) and/or
PIP5K which, in turn, regulates PIP2 formation [81]. We have
previously described a novel signal transduction module in
breast cancer cells localized to the dominant leading edge
pseudopodia that, during hypoxia or serum deprivation,
increases invasive ability in human breast cancer cells by a
stimulation of the NHE1 via the NHERF1 directed and PKA-
mediated phosphorylation of RhoA at serine 188 and the
subsequent inhibition of RhoA and p38 activities [82,83]. We
hypothesize that the increased phosphorylation and altered
distribution of ezrin and its binding to phosphorylated NHERF1
during exposure to the ECM promotes invadopodia formation
and function and eventual invasion in that this signalsome re-
directs PKA to RhoA, which may include a RhoA-ROCK-p38
signal pathway that normally represses NHE1. The release of
this repression results in an increase in NHE1 activity and in
subsequent invasion. Accordingly, we favor the view that the
ß1-integrin receptor binding to the ECM directly facilitates the
assembly of a p-ezrin/p-NHERF1 protein complex that probably
includes the targeting of PKA to still undescribed sub-
membrane proteins to regulate NHE1 activity and subsequent
invadopodia formation and activity. Current studies in our
laboratory are addressing these interesting and potentially
important associations.
Invadopodia assembly is promoted by ECM signaling and
collaborations between integrins, the hyaluronan receptor
CD44 and growth factor receptors are probably the prerequisite
events for their formation and development. There is some
uncertainity concerning the relative importance and interaction
dynamics of the different ECM and growth factor receptors in
invadopodia initiation and development in that it is not yet clear
if the basic signal is integrin binding with followed by cross-talk
and/or transactivation with the other receptors. Here, we
observed that seeding the cells on crosslinked gelatin or on
matrigel stimulated the formation of invadopodia containing ß1
integrin and EGF receptors while CD44 was localized to the
membranes outside of the invadopodia. This suggests that
CD44 is not constituitively expressed in invadopodia but may
be recruited there only upon a sufficiently high concentration of
its agonist, hyaluronan, which can be concentrated at the
invasive front of tumors and may be important in cancer stem
cell-niche interactions [84]. As CD44 is directly associated with
adhesive podosomes [85], this presence outside of the
invadopodia could constitute the mechanism for general
adhesion of the cells to the Matrigel. Interestingly, the EGFR
was constituitively expressed in invadopodia even in the
absence of EGF and this would create an efficient mechanism
to permit the cells to rapidly increase invasive capacity upon
EGF becoming available. This ß1 integrin-mediated EGFR
recruitment and transactivation has been often reported in
cancer cells and suggested to be important for a concerted
regulation of invasion [86-88] (Morello et al., 2011; Morozevich
et al., 2012; Lau et al., 2012) but, here, we show for the first
time that this can occur inside ß1 integrin promoted
invadopodia.
In this study we aimed at elucidating the role of the
phosphorylation of ezrin and its binding to PIP2 and their
possible synergism with respect to activation of ezrin’s
orchestration of the multiprotein complex in the invadopodia
and invadopodia activity. Altogether these results suggest that
both the activation of ezrin and its interaction with PIP2 are
indispensable in controlling invadopodial NHE1 activity and the
consequent focal proteolytic capacity. Furthermore, the
stimulation of cancer cells to develop invadopodia by plating on
ECM, occurs through the formation of a a lipid raft
compartmentalized functional protein-lipid-protein “signalsome”
formed by NHE1, p-ezrin, PIP2, ß1-integrin and p-NHERF1
that promotes this activation of NHE1. The present study adds
ezrin in its T567 phosphorylated state as an important player in
the race for understanding the molecular mechanisms behind
the cancer invasive process. We believe that p-ezrin could
serve as a marker potentially applicable to the detection and
identification of pre-symptomatic cancers and, secondly, could
be exploited as a therapeutic target in those cancers.
Materials and Methods
Patients
Surgical specimens of breast cancer were obtained from 75
consecutive patients with a first diagnosis of primary breast
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cancer histologically confirmed at the Department of Pathology,
Anatomic Pathology A Unit, Istituto Nazionale Tumori, Milan,
Italy. Before undergoing routine surgery, all patients signed an
informed consent authorizing the Institute to utilize their
removed biological tissues for research purposes. Approval
was obtained from the Institutional Ethics Board (Dr. Roberto
Satolli, president, email: segreteriaCEI@istitutotumori.mi.it) of
the National Institute for the Study and Cure of Tumors
(IRCCS) of Milano, Italy and is in full agreement with the
principles of the Declaration of Helsinki. Routine staging
procedures were adopted for determination of stage disease
extension according to UICC criteria [89]. The patients
underwent surgery before receiving any therapy. Just after
surgical removal of biological tissues, the pathologist selected
from the primary tumor and from contiguous macroscopically
not involved breast tissues samples destined to routine
diagnostic practice and to research activities. The
characteristics of these tissue samples have been successively
confirmed by H&E histological analysis. The cytohistological
tumor differentiation grade and hormone receptors (Estrogen
Receptor, ER, and Progesterone Receptor, PgR) expression
were determined by immunohistochemical assays and
categorized as positive or negative cases according to the cut-
off value of 10% of positive immunostained cells. Estrogen and
Progesterone and their receptors play important roles in the
genesis and malignant progression of breast cancer; they are
the prototype predictive markers in oncology. Tumor
proliferative activity was determined as the percentage of tumor
cells expressing the growth-related Ki67 antigen by
immunohistochemical assay. The Nottingham Prognostic Index
(NPI) combining tumor size, lymph node stage and histological
grade information was utilized to score each patient in which
patients with NPI values < 2.5 have an expected best
prognosis, with NPI = 2.5–3.5 have an expected intermediate
prognosis and with NPI > 4.5 are associated with poorest
prognosis [60].
Immunohistofluorescence
Immunohistofluorescence studies were performed on
formalin-fixed tissue sections embedded in paraffin wax. The
breast cancer tissues, obtained from patient breast biopsy
specimens, were fixed in 20% neutral buffered formalin for 24
hours and embedded in paraffin. Serial sections of 3 micron in
thickness were obtained from tissue blocks, deparaffinized with
xylene and rehydrated in an ethanol series. Microwave
pretreatment (slides were immersed in a 10 mM citrated buffer,
pH 6.0, at 95°C, 15 min total) for antigen retrieval was carried
out prior to incubation with primary antibody. After cooling,
slides were washed in distilled water, treated 10 min with 0.2%
BSA to block nonspecific protein binding, washed in water for 5
min and then incubated with p-ezrin (1μg/100μl) and/or HER2
(monoclonal H1alpha67, 1:300, Abcam, Cambridge, UK)
antibody overnight at 4°C in a humidified chamber. Positive
tissue controls of the breast carcinoma as well as negative
control slides that were run simultaneously were used to
assess the quality of immunostaining. For negative controls,
slide sections that were positive for staining were treated with
0.2% BSA instead of the primary antibody. No staining was
observed in any of these controls. Images were obtained on a
BX40 microscope (Olympus) with a SenSys 1401E-
Photometrics CCD camera.
Statistical Procedures
In the clinical measurements, Ezrin and p-Ezrin expression
were quantified by two independent observers and evaluated in
each case as negative or positive, where the positivity was
assigned when ≥ 30% of the tumor cells expressed Ezrin
and/or p-Ezrin. Each case was scored as with cytoplasmic
Ezrin localization vs. cell membrane localization, when ≥ 30%
of the tumor cells expressed Ezrin in the cytoplasm or in the
cell membrane. Each case was classified as cytoplasmic Ezrin
localization vs. cell membrane localization, where the result of
a trial only determines whether or not the specified event has
occurred (cytoplasmic/membrane localization). Modelling using
a binomial distribution gave the empirical estimate is the
maximum likelihood estimate. The binomial distribution is the
discrete probability distribution of the number of successes in a
sequence of n independent yes/no experiments, each of which
yields success with probability p. The empirical probability
(ratio of the number of outcomes in which a specified event
occurs to the total number of trials) is an estimator of a
probability, while the standard deviation of a binomial
distribution can be calculated as σ = (n*p*(1-p))1/2. Kruskal-
Wallis non-parametric ANOVA test was applied to analyze
ezrin/p-ezrin expression between different grades and NPI
stages while the Mann-Whitney non-parametric test was
applied to normal and tumor tissues, age, menopausal status,
size, node status and the positive vs negative classes of PgR
and Ki67. The negative classes were defined as tumors having
values below 20 in IHC analysis. Correlation analysis for
ezrin/p-ezrin expression and PgR, Ki67 and HER2 expression
were performed with the Spearman-Rank non-parametric test.
In the in vitro experiments, student’s t-test was applied to
analyze the statistical significance between treatments in which
P < 0.05 was considered as significant. All comparisons were
performed with InStat (GraphPad Software).
Cell culture and transfection of constructs
MDA-MB-231 cells were cultured as previously described
[83]. The following mutated ezrin constructs were made to
better dissect the relative importance of its phosphorylation and
PIP2 binding capacity on invadopodia proteolytic function. The
T567 domain was mutated to either no longer be able to be
phosphorylated (T567A) or to mimic phosphorylation (T567D)
while it was mutated in the in the PI(4,5)P2 (PIP2) binding
domain (PIP2-) to block this capacity. Briefly, we used full-length
human ezrin cloned into pEGFP-N1 and mutated at threonine
567 by site-directed mutagenesis [90,91]. Mutations in the PIP2
binding region of ezrin [92] were introduced by substituting four
lysines (positions 253, 254, 262 and 263) with four asparagines
via site-directed mutagenesis using the following primers:
CAGGAACATCTCTTTCAATGACaataatTTTGTCATTAAACCC
ATCGACAAG (K253N/K254N) and
GTTTGTCATTAAACCCATCGACaataatGCACCTGACTTTGT
GTTTTATG (K262N/K253N). Mutations were generated using
the QuikChange II Site-Directed Mutagenesis kit (Agilent
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Technologies, Santa Clara, CA) according to manufacturer’s
instructions. To produce the myc-tagged version of ezrin and
ezrin mutants, the pEGFP-N1 vector (Clontech, Mountain View,
CA) was digested with AgeI and BsrGI and religated with myc-
containing oligonucleotide adaptor. All constructs were
sequence-verified. The phospho(T567) ezrin inhibitor,
NSC668394 (NSC), was purchased from EMD Millipore.
Further, a wild-type (WT) NHE1 construct (WT-NHE1-HA)
and NHE1 constructs mutated in the PIP2 (KR/A 513-520-
NHE1-HA) or ezrin (KR/A 556-564-NHE1-HA) binding domains
to no longer bind in those regions were generously supplied by
Prof. J. Orlowski of the University of Toranto, Canada.
For transfection, 10 µg plasmid cDNA or empty vector was
incubated with 100 µl of LipoTaxi Transfection Reagent
(Stratagene, USA) and applied to cells as per manufacturers
instructions.
Matrigel@ layer preparation and invadopodia activity
assay using in situ zymography
For in vitro dequenching assay, experiments were conducted
in Matrigel™ (diluted to a final concentation of 4mg/ml)
containing quenched BODIPYs linked to BSA (DQ-Green BSA)
as described [9]. Focal proteolysis produces fluorescence in a
black background which is used both to quantify proteolytic
activity levels and in co-localization analysis. ‘Pericellular’
digestion is defined as that low level of digestion around the
cell that is outside of the strong, focal digestion characterized
by invadopodia activity. We obtain this by measuring the level
(pixel density) of the release of fluorescence underneight the
entire cell while the level of focal digestion/proteolysis is
obtained by selecting each focal proteolytic point in each cell
and measuring the pixel density. As in the traditional method,
each cell can have more than one focal point of digestion.
Therefore, the mean pixel density for each cell is the sum of all
those contained that cell. There is always a certain number of
cells that are negative for focal invadopodial digestion (again
as in the traditional technique). The quantity of invadopodia
activity was determined with the following measurements: (i)
percent of cells with active invadopodia, (ii) number of
invadopodia per active cell, (iii) pixal density of digestion
performed by individual invadopodia and from these measures
the mean total actual invadopodia proteolytic activity for 100
cells was then calculated: Invadopodia Index = percentage of
Invadopodia-positive cells (proteolitically-active areas also
positive for both actin/cortactin) x mean number of
invadopodia/cell.
Cross-linked gelatin layer preparation and invadopodia
fractionation
Porcine skin gelatin was dissolved to a final concentration of
2mg/ml in PBS containing 2mg/ml of sucrose by a slight
warming in a microwave oven and 15 ml of this gelatin solution,
kept warm at 40°C, was spread on 150mm diameter plastic
dishes to evenly cover the entire dish surface. Excess gelatin
was removed and the remaining layer was allowed to gel on ice
for 10 min. Then 10 ml of ice cold, 0.5% glutaraldhyde in PBS
was added to each dish to cross-link the gelatin on ice for 15
min with gentle shaking. The cross-linked gelatin was then
washed three times with PBS for 5 min and 20 ml of 70%
ethanol was added to each dish for 1hr under a sterile bench
hood to sterilize. The gelatin layer was washed two times with
sterile PBS for 5 min and two times with complete DMEM, the
last wash of DMEM was not removed and the dishes were left
in a humified, 37°C incubator for 1hr followed by seeding
4,000,000 cells on each dish. After 24 hr in a humified, 37°C,
5% CO2 incubator, cell fractions were isolated as follows: each
dish was washed three times with PBS containing 1mM CaCl2
and 0.5mM MgCl2, two times with 0.2 X PBS plus 1mM CaCl2
and 0.5mM MgCl2. Cells were then incubated on ice with 3ml of
hypertonic swelling buffer (0.2 X PBS supplied with 2μl/ml
protease inhibitor cocktail (Sigma), PMSF 1mM, sodium
orthovanadate 1mM) for 15 min on ice. Cell bodies were gently
scraped with an L-shaped pasteur and centrifuged at 10,300 X
g for 30 min. Supernatant was collected (cytosolic soluble
proteins) and placed on ice while the pellet was resuspended
with 100μl of lysis buffer (Hepes 5mM, EDTA 0.5mM, pH7.2
supplied with protease inhibitor 2μl/ml, PMSF 1mM, sodium
orthovanadate 1mM, DTT 1mM, nonidet 0.1%) and membrane
proteins were extracted by 30 min of rotating at 4°C. After two
washes with PBS, the entire gelatin layer containing entrapped
invadopodia was scraped from the dish with 1ml of above lysis
buffer. The collected gelatin was vortexed and protein
extracted for 30 min on an orbiting wheel at 4°C. The fractions
containing membrane proteins or invadopodia were collected in
eppendorf tubes and centrifuged at 13,000 X rpm at 4°C. The
supernatant of each fraction was collected and the pellet
discarded. The diluted samples were concentrated by
centrifugation at 10,300 X g for 1hr and protein concentration of
the three fractions were measured with Bradford (Pierce). For
Western Blotting, proteins were resuspended in SDS sample
buffer (6.25 mM Tris-HCl, pH 6.8, containing 10% glycerol).
Invasion across Matrigel@ layer in Boyden Chambers
A quantitative measure of the degree of in vitro invasion of
MDA-MB-231 cells was measured as the ability to traverse a 8
µm polycarbonate membrane coated with 5 µg matrigel
(Chemicon Int., Livermore, CA) as previously described [82].
The fluorescent samples were read in a fluorescence plate
reader at 480/520 nm (Cary Eclipse Fluorescence
Spectrophotometer, Varian). Mean ± S.E., n=5, ***p<0.001 and
n.s. is not significant.
Co-immunoprecipitation
After treatment, fractions were prepared in ice-cold co-
immunoprecipitation lysis buffer (50 mM Tris [pH 7.5], 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 100 µM Na 3VO4,
1 mM NaF, protease inhibitors). An aliquot was removed for the
determination of total cellular protein. Approximately 300 µg
protein of the membrane or invadopodia fractions was
incubated for 1 hour at 4°C on a rotator with 1µg of primary
antibody. 5µl of resuspended volume of Protein A/G PLUS-
Agarose (Santa Cruz Biotechnology, CA) was then incubated
at 4°C on a rotator overnight. Immunoprecipitates were
collected by centrifugation at 2,500 rpm for 5 minutes at 4°C.
Supernatant was carefully aspirated and discarded and the
pellet washed 4 times with 1 ml lysis buffer, each time
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repeating centrifugation step above. After the final wash, the
pellet was resuspended in 40 µl of sodium dodecyl sulfate
(SDS) sample buffer (6.25 mM Tris-HCl, pH 6.8, containing
10% (v/v) glycerol, 3mM SDS, 1% (v/v) 2-mercaptoethanol and
0.75 mM of Bromophenol Blue) and was run on 10% SDS-
PAGE, blotted to ImmobilonP and analyzed by Western
Blotting with polyclonal p-ezrin antibodies diluted 1:2000 and/or
HER2 (monoclonal H1alpha67, 1:300, Abcam, Cambridge, UK)
Immunofluorescence
Cells plated on coverslips or colonies on matrigel were
washed 2 times in sterile PBS at room-temperature, fixed with
3.7% ice-cold paraformaldehyde/PBS for 20 min. The fixed
cover-slips were washed 3 times for 5 min each with ice-cold
PBS, the colonies permeabilized with 0.1% TRITON X-100 for
10 min and then saturated with 0.1% gelatin in PBS for 10 min.
The coverslips were incubated with polyclonal anti-NHERF1
primary antibody (Affinity BioReagents, Golden, CO) diluted
1:300 in 0.1% gelatin in PBS at RT for 1 hr, washed 3 times for
5 min each with 0.1% gelatin in PBS and incubated at RT for 1
hr with the ALEXA 488 goat anti-rabbit IgG secondary antibody
conjugate (Molecular Probes, Eugene, OR). The coverslips
were then washed 3 times with ice-cold PBS for 5 min each,
rapidly rinsed in dH2O and then mounted with Mowiol
(CalBioChem, San Diego, CA). Proteins were detected with
either a Nikon TE 2000S epifluorescence microscope equipped
with a MicroMax 512BFT CCD camera (Princeton Instruments,
NJ) using a Nikon lamp shutter with a mercury short arc photo
optic HBO 103 W/2 lamp for excitation (OSRAM GmbH,
Augsburg, Germany). In co-localization experiments, cells were
observed at 600X magnification in oil immersion with a laser
scanning confocal microscope (LSCM) (C1/TE2000-U; Nikon
Instruments SpA, Sesto Fiorentino–FI, Italy) equipped with
He/Ne 633 and Argon 488 lasers with 495–519 (B2-A) and
642–660 (Cy5) nm excitation filters. All images were taken
under Plan Apo 60XA/1.40 NA oil objective (Nikon, Japan). For
each cell or tissue section, scanning was conducted with 25-30
optical series from the top to the bottom of the cell with a step
size of 0.45 µm. Parameters related to fluorescence intensity
were maintained at constant values in all measurements.
Image analysis
For every image a Z-stack was acquired using the
Metamorph software (Universal Imaging Corp, West Chester,
PA) and every three color stack (red, green and blue) is the
sum of 3 stacks (one for each color) acquired separately in
black and white (B/W). Before image analysis, each stack is
deconvolved using the AutoDeblur 9.1 function of the
AutoQuant software (Troy, N.Y.) and then merged by
transforming the three channels corresponding to red, green
and blue into a single two color stack using the ‘RGB merge’
command of the ImageJ© software. To verify colocalization, the
three separate B/W stacks were analyzed with the
‘colocalization’ plugin of ImageJ with a ratio of 97, threshold of
50 for both channel 1 and 2. By then selecting the ‘colocalized
points (8 bit)’ option a new stack is obtained where the
colocalized pixels appear white on a black background. This
stack is then converted into a voxel-gradient (VG) shading
function of AutoVisualize© (AutoQuant software, Troy, N.Y)
which permits the observation of the 3D colocalization zones in
a volume.
The random or co-dependent nature of the above calculated
‘apparent’ dye-overlap colocalizations were tested using (i)
Intensity Correlation Analysis (ICA) in which the distribution of
the intensity value (normalized to 1) for each pixel of a channel
is plotted against the the product of the difference of the mean
(PDM) of the two channels are determined and (ii) the Li
Intensity correlation quotient (ICQ) calculated [93]. Both ICA
and ICQ were calculated using the JACoP image analysis
package plugin in ImageJ. Apparent colocalization due to
random staining or very high intensities in one window will have
an ICQ near zero while if the two intensities are interdependent
(colocalized) the values will be positive with a maximum of 0.5.
In addition to giving information on cellular localization of the
proteins, the ICA-ICQ analysis is useful for identifying potential
low-affinity interactions within protein complexes that may be
missed in high-affinity co-immunoprecipation or pull-down
experiments.
Isolation of Raft and Nonraft fractions
Raft (pellet) and nonraft (supernatant, Supernat) fractions
were separated from the above membrane and invadopodia
fractions by incubating the fractions (100 µg protein) at 4°C
with lysis buffer containing 1% of Lubrol. Insoluble material was
formed into pellets (by centrifugation at 100,000 X g for 1 hour),
and equal amounts of the resuspended pellet (P) and the
supernatant (SN) were analyzed by SDS-PAGE and Western
blotting.
Cholesterol depletion
Membrane cholesterol was depleted, as previously described
[94], by suspending cells in extracellular solution containing 1
mM Methyl-β-cyclodextrin (MβCD) for 1 hr at 37 °C. For ECM
proteolysis imaging experiments, transduced cells were
incubated in the DMEM-based culture medium containing 1
mM MβCD for 1hr at 37°C. MβCD treatment significantly
reduced the membrane cholesterol content as detected by
staining with the fluorescent polyene antibiotic filipin (Sigma-
Aldrich) that forms complexes with cholesterol (Figure S4).
Control or MβCD-treated cells were fixed in 3.7% formaldehyde
in phosphate-buffered saline (PBS) for 10–15 min. After
rinsing, cells were incubated with PBS containing 0.05 mg/ml
filipin (Sigma-Aldrich) and 10% fetal bovine serum.
Fluorescence images were obtained using a D350/50x
excitation filter, E420LP dichroic mirror, and a 400 DCLP
emission filter.
Supporting Information
Figure S1.  Activation of ß1 integrin stimulates
invadopodia ECM proteolysis by inducing phosphorylation
of ezrin at T567. A. To determine the effect of specific ß1
integrin activation on p-ezrin levels, MDAMB-231 cells were
treated with 5mg/ml of the activating antibody P4G11 (Santa
invadopodia Ezrin T567 Phosphorylation
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Cruz Biotechnologies, sc-18845 L) for the indicated times and
the levels of p(T567)-ezrin were measured in Western Blot.
B. To examine the role of ezrin T567 phosphorylation in ß1
integrin stimulation of invadopodial-dependent focal digestion
of the ECM, MDA-MB-231 cells were treated with 5mg/ml of
the activating antibody P4G11 in the absence or presence of
3μM of the inhibitor of ezrin T567 phosphorylation, NSC668394
(NSC). Cells were plated on Matrigel with DQ-Green BSA and,
24 hr later, ECM digestion was analyzed in confocal
microscopy for a series of individual cells as described in
Methods. Mean ± S.E.M., n=4, ***p<0.001 and *p<0.05 for
focal proteolysis compared to the control cells.
(TIF)
Figure S2.  CD44 localization in invadopodia and
interaction with pezrin and ECM digestion. A. To better
visualize invadopodial focal digestion and protein localization in
Matrigel, we utilized the in situ zymography technique using the
quenched fluorescent substrate, DQ Green-BSA, such that a
quantifiable fluorescence is released only upon digestion of the
matrix. Cells seeded on Matrigel were allowed to digest the
fluorigenic substrate and after fixation cells were assayed in
immunofluorescence. Confocal images in axial planes taken at
the bottom of the cells (XY) of a typical cell incubated on
Matrigel overnight show p-ezrin (blue), CD44 (red) and
digestion (green) localization. For the field, XZ zoomed
sections of the above representative regions of interest (white
box) are shown at the side. As can be seen in green, low levels
of basal, diffuse digestion were observed under and around the
cells together with more restricted areas of high levels of focal
digestion.
Importantly, p-ezrin (blue) and digestion (green) were co-
localized in protrusive digestive structures on the ventral cell
surface while CD44 (red) is localized to the cell plasma
membrane outside of invadopodia (see RGB plot for a typical
zone). ICA analysis plots using the JACoP image analysis
plugin in ImageJ for CD44/p-ezrin displayed hour-glass curves
for the co-localization of CD44 and p-ezrin and for CD44/
digestion demonstrating no significant co-localization of CD44
with either digestion or p-ezrin (ICQ = 0.036 ± 0.015; n.s.).
Scale bars = 10 μm(XY) and 5 μm (XZ).
B. CD44 binds to p-ezrin and NHE1 primarily in the membrane
fraction. MDA-MB- 231 cells were seeded for 24 hr on 2%
gelatin and cytosol, cell body membrane and invadopodia
fractions were separated as above. Each cell membrane or
invadopodia fraction was then immunoprecipitated with anti-
NHE1 or anti-p-ezrin and the precipitated immunocomplex was
probed for the expression of CD44 by Western Blot. Input for
CD44 was measured by Western Blot of the total input with the
same antibodies. Representative blot of 4 independent
experiments.
(TIF)
Figure S3.  p-ezrin and ß1-integrin receptor co-localize
with areas of focal digestion of Matrigel. A. Confocal images
of a typical cell incubated on Matrigel overnight show p-ezrin
(blue), ß1-integrin (red) and digestion (green) co-localization in
protrusive digestive structures on the ventral cell surface. To
the left of the image are two representative XY areas with their
RGB profiles showing a very high co-localization of the two
proteins with areas of proteolysis while under the image are
two representative XZ constructions of proteolytic focal spots
with their RGB profiles showing a very high co-localization of
the two proteins with areas of proteolysis along the whole
invadopodia. Scale bars = 10 μm(XY) and 5 μm (XZ).
B. To further analyze the potential direct association between
p(T567)-ezrin and ß1 integrin at proteolytically active
invadopodia, we used an in situ Proximity Ligation Assay (in
situ PLA) (Duolink II Kit; Olink Bioscience, Uppsala, Sweden),
which can detect endogenous protein-protein interactions that
occur within 40 nm (Soderberg et al., 2008). We combined this
with our Matrigel degradation assay, in which cells are plated
on a mixture of Matrigel containing DQGreen BSA-Bodipy and
a green fluorescent emission staining is indicative of
invadopodia driven-ECM digestion. The advantages of PLA are
that this technique provides a fluorescent signal (red) only
when two target proteins are colocalized, allowing improved
sensitivity for establishing endogenous protein-protein
interactions and giving in situ information whether these co-
localizations occur in specific intracellular compartments.
Indeed, as shown by the red fluorescent staining reported here
(upper left panel), p-ezrin associates with ß1 integrin in a large
subset of foci of degraded matrix. Interestingly, there are a
couple of ‘digestive’ podosome (doughnut shaped structures,
white arrows) where proteolysis occurred mostly within the
circle. These results demonstrate that some sub-populations of
p-ezrin and ß1 integrin closely interact in functionally active
invadopodia where they probably both interact with NHE1.
Scale bar = 10 μm.
Söderberg et al., Characterizing proteins and their interactions
in cells and tissues using the in situ proximity ligation assay.
Methods. 2008 45(3):227-232.
(TIF)
Figure S4.  Effect of MβCD treatment on membrane
cholesterol content detected by filipin staining. In order to
visualize the efficiency of MβCD treatment to deplete
membrane cholesterol content, cells were incubated with the
polyene antibiotic filipin which forms multimeric globular
complexes with membrane cholesterol that can be visualized
by fluorescence microscopy, was used to verify that MβCD
treatment effectively depleted membrane cholesterol. Scale bar
= 10 μm.
(TIF)
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